Shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB – Free Report) are scheduled to reverse split on Monday, September 28th. The 1-15 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, September 27th.
Matinas Biopharma Stock Down 1.6%
Shares of NYSEAMERICAN MTNB opened at $0.16 on Friday. Matinas Biopharma has a twelve month low of $0.15 and a twelve month high of $2.14. The firm has a fifty day simple moving average of $0.24 and a 200 day simple moving average of $0.50. The company has a market capitalization of $2.36 million, a PE ratio of -0.14 and a beta of 1.70.
Matinas Biopharma (NYSEAMERICAN:MTNB – Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($0.21) earnings per share (EPS) for the quarter.
About Matinas Biopharma
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company focused on developing oral formulations of medicines that are traditionally administered by injection. The company’s technology platform, known as lipid nanocrystal (LNC) technology, is designed to encapsulate active pharmaceutical ingredients and support their delivery through the gastrointestinal tract.
Matinas’ lead investigational product is MAT2203, an oral formulation of amphotericin B, an antifungal medicine used to treat serious fungal infections.
Featured Articles
- Five stocks we like better than Matinas Biopharma
- Lennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing
- Priced for a Pullback or More Gains? These 3 Stocks Are Testing the Limits
- These 3 Agentic AI Stocks Have More Than Hype Behind Their Growth Stories
- Not Just Banks: 3 Trading Stocks to Watch After the Fed Rate Hike
Receive News & Ratings for Matinas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
